BET Proteins and T-Cell Function: Joseph A. Fraietta, PhD
The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed his research into the mechanisms of the BET protein family and T cells.
Challenging Paradigms in AMD: Gregory S. Hageman, PhD
The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed his team’s research in the role of HTRA1.
Improving Safety With CAR Engager Proteins
Paul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s research on CAR T therapies.
Expanding the Use of CAR T Therapy With shRNA
The chief executive and chief medical officers of Celyad Oncology discussed the company’s future research and plans.
Optimizing Manufacturing of NK Cell and CAR T Therapies for Cancer Treatment
Jan Davidson, MD, PhD, chief medical officer, Wugen, discussed the company’s cell therapy platforms.
Integrating CAR T Therapy in Multiple Myeloma: Krina K. Patel, MD, MSc
The associate professor from The University of Texas MD Anderson Cancer Center discussed the integration of CAR T-cell therapy into the treatment paradigm of R/R MM.
CAR T-Cell Utility in Hematologic Cancers: Alex Herrera, MD
The hematologist and oncologist from City of Hope discussed the utility of CAR T cells in patients with hematologic cancers.
Addressing Exhausted T-Cells in CAR T Therapy: Joseph A. Fraietta, PhD
The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed the issue of exhausted T-cells.
Developing Natural Killer Cell Therapies for Hematologic Malignancies and Solid Tumors
The chief executive and medical officers of Cytovia Therapeutics discussed their natural killer cell therapy technology.
Developing MCO-010 for Retinal Degenerative Diseases
Samarendra Mohanty, PhD, cofounder and president, Nanoscope Therapeutics, discussed the company’s technological platforms and RESTORE trial data.
RNA-Modified vs DNA-Modified CAR T Products
Michael Singer, MD, PhD, chief scientific officer, Cartesian Therapeutics, discussed the company’s RNA Armory technology.
Future Research With CAR T Therapy in Multiple Myeloma: Frits van Rhee, MD, PhD
The professor and director of the myeloma center at the University of Arkansas for Medical Sciences discussed future research with CAR T in multiple myeloma.
Elucidating the Role of HTRA1 in Developing AMD: Gregory S. Hageman, PhD; Brandi L. Williams, PhD
Directors from the Moran Eye Center discussed their research on the genetics of age-related macular degeneration.
Addressing High Relapse Rates in CAR T-Cell Therapy
Paul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s CAR T Engager protein technology.
Rationale and Future of Ide-Cel: Larry D. Anderson, Jr, MD, PhD
The hematologist/oncologist at the Harold C. Simmons Comprehensive Cancer Center discussed the rationale behind using CAR T-cell therapy in relapsed/refractory multiple myeloma and data from the KarMMa trial.
Using Cell Therapies for Cancer and Beyond
Jennifer Buell, PhD, president and chief operating officer of Agenus, discussed cell therapy for multiple myeloma and COVID-19 respiratory distress.
CARTITUDE Trials in Multiple Myeloma
Experts discussed safety and efficacy data of cilta-cel for R/R MM from the CARTITUDE-1 and CARTITUDE-2 studies.
Addressing Unmet Needs With Gene Therapy
Eric Crombez, PhD, senior vice president and chief medical officer of Ultragenyx Gene Therapy, discussed indications the company is targeting.
Gene Therapy for Retinal and Neurological Diseases
Magali Taiel, MD, chief medical officer, GenSight Biologics, discussed future research the company plans to pursue.
Investigational Agents in Relapsed/Refractory Myeloma
Experts discuss emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia
The hematologist from UC Health discussed the role of allogeneic stem cell transplant at first remission based on risk stratification.
Future CAR T Therapy Research in Multiple Myeloma: Krina K. Patel, MD, MSc
The associate professor from The University of Texas MD Anderson Cancer Center discussed future research with CAR T therapy in multiple myeloma.
Emerging Data in Diffuse Large B-Cell Lymphoma
Experts discussed data from trials in lymphoma presented at ASCO 2021.
CAR T-Cell Therapy's Potential in Non-Hodgkin Lymphoma: Julie Vose, MD
The chief of Oncology and Hematology at University of Nebraska Medical Center, discussed the potential utility of CAR T-cell therapy across the non-Hodgkin lymphoma (NHL) paradigm.
Using A Modular Approach to Develop Oncolytic Cell Therapies
The chief executive and chief medical officers of Celyad Oncology discussed their platform and positive data presented at EHA 2021.
The Future of Gene Therapies in Inherited Retinal Diseases
Mariya Moosajee, MBBS, BSc, PhD, FRCOphth, discussed the next generation of gene therapy for inherited retinal diseases.
Investigating the Role of HTRA1 in Developing AMD: Brandi L. Williams, PhD
The research director at the Moran Eye Center discussed the genetics of developing age-related macular degeneration.
Treatment Options After CAR T Therapy for Large B-Cell Lymphoma
The professor of medicine from Duke University School of Medicine discussed treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.
Tackling Dravet Syndrome With Gene Therapy
Salvador Rico, MD, PhD, chief medical officer, Encoded Therapeutics, discussed the different initiatives the company is conducting in Dravet syndrome.
Addressing Unmet Needs in Mantle Cell Lymphoma With CAR T Therapy: Anita Kumar, MD
The medical oncologist from Memorial Sloan Kettering Cancer Center discussed efforts made to address areas of unmet need in mantle cell lymphoma.
